HAIC Combined With Durvalumab and Tremelimumab and Lenvatinib in uHCC

S

Sulai Liu

Status and phase

Enrolling
Phase 2

Conditions

Hepatocellular Carcinoma

Treatments

Drug: HAIC+STRIDE+Len

Study type

Interventional

Funder types

Other

Identifiers

NCT06364007
SLiu0401

Details and patient eligibility

About

The treatment options for unresectable HCC have rapidly developed, and immunotherapy has shown significant survival benefits in hepatocellular carcinoma. The STRIDE regimen of Single Tremelimumab (high, priming 300-mg dose) Regular Interval Durvalumab (1500 mg every 4 weeks) improved OS vs sorafenib in pts with unresectable HCC. In Asian region, HAIC is applied for HCC patients who are not suitable for surgical resection or local ablation treatment. Retrospective studies suggested a potent antitumor effect and survival benefit of HAIC plus programmed death-1 inhibitor and Lenvatinib. This phase II study was aimed to evaluate the efficacy and safety of STRIDE plus lenvatinib, given concurrently with HAIC in pts with unresectable HCC.

Enrollment

20 estimated patients

Sex

All

Ages

18 to 70 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • Age 18 ~ 70 years old (including 70 years old), male and female;
  • Patients with hepatohcellular carcinoma diagnosed clinically or confirmed by histology / cytology ;
  • Patients with unresectable or metastatic hepatocellular carcinoma;
  • No systematic treatment. Patients recieved previously systematic treatment and progressed can also be included in the group;
  • Patients who underwent hepatectomy in the past should be R0 resection, and the tumor recurrence should be more than 6 months after operation;
  • At least one assessable lesion (mRECIST criteria);
  • Expected survival time ≥ 3 months;
  • ECOG 0 ~ 1;
  • Child Pugh ≤ 7;
  • Be able to cooperate to observe adverse events;

Major organs are functioning normally:

  • Hemoglobin ≥ 90 g / L;
  • ANC ≥ 1.5 × 109/L;
  • Platelet count ≥ 75 × 109/L;
  • Albumin ≥ 28 g / L;
  • Total bilirubin ≤ 2 × ULN;
  • AST, ALT ≤ 5 × ULN;
  • ALP ≤ 5 × ULN;
  • Creatinine ≤ 1.5 × ULN;
  • INR or PT ≤ 1.5 × ULN; J) APTT ≤ 1.5 × ULN。

Exclusion criteria

  • History of symptomatic congestive heart failure, unstable angina pectoris,
  • Uncontrolled cardia arrhythmia
  • History of hepatic encephalopathy
  • Uncontrolled arterial hypertension
  • Co-infection with HBV and HDV

Trial design

Primary purpose

Treatment

Allocation

N/A

Interventional model

Single Group Assignment

Masking

None (Open label)

20 participants in 1 patient group

Treating with a Designed Protocol
Experimental group
Treatment:
Drug: HAIC+STRIDE+Len

Trial contacts and locations

1

Loading...

Central trial contact

Chuang Peng, PhD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems